Zobrazeno 1 - 10
of 14
pro vyhledávání: '"L López-Esteban"'
3PC-057 Economic impact after the implementation of a risk matrix in the preparation of chemotherapy
Autor:
A Cidoncha-Berlanga, M Labrador-Paniagua, T Molina-García, R Diez-Fernández, R Gardón-Pérez, M Hijazi-Vega, L López Esteban, Má Esteban-Pérez, I Bueno-Florido
Publikováno v:
Section 3: Production and Compounding.
Background National Guide of Good Preparation Practice for Medicinal Products in Hospital Pharmacy Departments (HPD) (2014) recommends the use of a risk matrix (RM) to assess the risks during the preparation and ensure the quality of the finished pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2b837e9a0be1e58dcf182d45d95378a
https://doi.org/10.1136/ejhpharm-2019-eahpconf.138
https://doi.org/10.1136/ejhpharm-2019-eahpconf.138
Autor:
L López Esteban, P. López Méndez, AM Sánchez Peña, R Diez Fernandez, T Molina García, M Hijazi Vega
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Malignant mesothelioma (MM) is a rare cancer, considered an occupational disease in many patients. Incidence is increasing worldwide mainly because of professional exposure to asbestos. MM patients have limited therapeutic options with poo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09a3b888b239b97b9c3523afebdc6768
https://doi.org/10.1136/ejhpharm-2019-eahpconf.378
https://doi.org/10.1136/ejhpharm-2019-eahpconf.378
Publikováno v:
Clinical pharmacy.
Background Immune thrombocytopenia (ITP) is an autoimmune disease characterised by isolated thrombocytopenia (platelet count 9 /L, without surpassing a maximum dose of 10 µg/kg. There are concerns that starting doses may be too low to obtain normali
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd575538e70b0ad2f048dbed7493f5f4
https://doi.org/10.1136/ejhpharm-2017-000640.93
https://doi.org/10.1136/ejhpharm-2017-000640.93
Autor:
J Sánchez-Rubio Ferrández, L López Esteban, B Reques Sastre, C Martín Blas, A Onteniente González, T Molina García
Publikováno v:
European Journal of Hospital Pharmacy. 23:A82.3-A83
Background Knowledge of HIV+ patients about their disease and antiretroviral treatment (ART) has been associated with adherence and clinical outcomes. Purpose To determine the degree of knowledge about disease and treatment in HIV+ patients and to an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::baf6edf2782c7ea07244151e46bdd534
https://doi.org/10.1136/ejhpharm-2016-000875.187
https://doi.org/10.1136/ejhpharm-2016-000875.187
Publikováno v:
European Journal of Hospital Pharmacy. 23:A79.1-A79
Background Cardiotoxicity is a known risk of anthracycline treatment. The probability of developing impaired myocardial function is estimated to be 1–2% at a total cumulative dose of 300 mg/m 2 of doxorubicin, whereas the risk dramatically increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89f749c4ff4cb12eb52f1000143ced22
https://doi.org/10.1136/ejhpharm-2016-000875.179
https://doi.org/10.1136/ejhpharm-2016-000875.179
Autor:
A Onteniente-González, B Reques Sastre, T Molina García, ME Martínez Nuñez, L López Esteban, R Vázquez Sánchez
Publikováno v:
European Journal of Hospital Pharmacy. 22:A39.2-A39
Background Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer. One of the most common side effects (affecting more than 10% of patients) associated with abiraterone is urinary tract infection (UTI). Purpose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b65de47ed2c43d72de8f317d31f40205
https://doi.org/10.1136/ejhpharm-2015-000639.94
https://doi.org/10.1136/ejhpharm-2015-000639.94
Publikováno v:
European Journal of Hospital Pharmacy. 22:A156.2-A157
Background Pharmacist review of drug prescriptions in the intensive care unit (ICU) has been shown to prevent errors and improve patient outcomes. However, it is necessary to evaluate the efficacy of interventions performed by pharmacists. Purpose To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c2e68c6f2165622b1c506c09de8a1bb
https://doi.org/10.1136/ejhpharm-2015-000639.377
https://doi.org/10.1136/ejhpharm-2015-000639.377
Autor:
L López Esteban, R Vázquez Sánchez, T Molina García, J Sánchez-Rubio Ferrández, B Reques Sastre, A Liras Medina
Publikováno v:
European Journal of Hospital Pharmacy. 22:A42.1-A42
Background Multiple sclerosis is a chronic inflammatory disorder of the central nervous system. Statins have demonstrated anti-inflammatory and immunomodulatory properties in this setting. Several clinical studies of different statins, given alone or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32fa91b08f90a470de73477f9fa90002
https://doi.org/10.1136/ejhpharm-2015-000639.100
https://doi.org/10.1136/ejhpharm-2015-000639.100
Autor:
J Sánchez-Rubio Ferrández, L López Esteban, R Vázquez Sánchez, ME Martínez Nuñez, T Molina García, B Reques Sastre
Publikováno v:
European Journal of Hospital Pharmacy. 22:A44.2-A44
Background Treatment of human immunodeficiency virus (HIV) infected patients usually involves the use of complex regimens and adverse effects. Current guidelines recommend treatment simplification in patients with effective infection control by switc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::192871a7feca075fd429519d87ae8c46
https://doi.org/10.1136/ejhpharm-2015-000639.105
https://doi.org/10.1136/ejhpharm-2015-000639.105
Publikováno v:
European Journal of Hospital Pharmacy. 22:A36.2-A37
Background Treatment outcomes and tolerability are not easily predicted in cancer patients receiving chemotherapy, especially in those patients with renal or hepatic dysfunction, where dose modifications become necessary. Purpose To evaluate drug dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d89e93da72ad9cb19fcb1b53863bf5fc
https://doi.org/10.1136/ejhpharm-2015-000639.87
https://doi.org/10.1136/ejhpharm-2015-000639.87